Status:
COMPLETED
Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China
Lead Sponsor:
GlaxoSmithKline
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40+ years
Brief Summary
This observational study will be conducted in COPD participants in Tier 2 and 3 hospitals in China to gain an understanding of the complex COPD management and physician's treatment strategy.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Male or female participants with minimum 40 years of age.
- A diagnosis of COPD confirmed by spirometry (According to Global initiative for chronic obstructive lung disease \[GOLD\] 2019 criteria) in Tier 2 and Tier 3 hospitals.
- In hospitalized participants, recruit only participants who receive any intravenous therapy.
- A signed and dated written informed consent.
- Participants can communicate normally.
- Exclusion criteria:
- Current primary diagnosis of asthma, active tuberculosis, bronchiectasis, lung cancer or other active pulmonary disease.
- Other unstable diseases or cognitive behavior, which could influence CAT and lung function results (judged by physicians).
- Experienced a moderate/severe COPD exacerbation treated by a physician within last 1 month.
- Currently participating in another COPD clinical study, which provides the participant investigational medication and/or disease management.
Exclusion
Key Trial Info
Start Date :
April 27 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 6 2023
Estimated Enrollment :
1507 Patients enrolled
Trial Details
Trial ID
NCT04853238
Start Date
April 27 2021
End Date
February 6 2023
Last Update
December 6 2024
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Huizhou, Guangdong, China, 516000
2
GSK Investigational Site
Jiangmen, Guangdong, China, 529100
3
GSK Investigational Site
Shaoguan, Guangdong, China, 512600
4
GSK Investigational Site
Shenzhen, Guangdong, China, 518020